Status:
RECRUITING
Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD)
Lead Sponsor:
InnoCon Medical
Collaborating Sponsors:
Aarhus University Hospital
Odense University Hospital
Conditions:
Urinary Incontinence
Urinary Incontinence, Urge
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
UCon is a medical device for treatment of the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the ...
Detailed Description
The overall purpose of the current clinical investigation is to evaluate the medical device with a UCon-Bar Electrode with respect to its initial safety and device performance in a cohort of 40 female...
Eligibility Criteria
Inclusion
- Participant is female
- Participant is ≥ 18 years of age.
- Participant is diagnosed with OAB or BD.
- OAB: Urinary urgency usually with one or more of the following:
- i. Urinary urgency incontinence (≥1 per/week). ii. Urinary frequency (≥8 voiding/day without polyuria). iii. Nocturia (≥2 voiding/night without nocturnal polyuria).
- BD: One or more of the following:
- i. Faecal urgency (≥3 urgencies pr. week) together with registration of urgency in St. Mark´s and a St. Mark´s score ≥9.
- ii. Faecal incontinence (urge/passive) (≥1 per/week).
- Participant is able to communicate, provide feedback, understand and follow instructions during the course of the investigation, including using the device at home.
Exclusion
- Participant is medically unstable (acute illness or complication of a chronic condition, apart from the OAB or BD, that might affect the participants´ participation in the investigation).
- Participant has an active infection in the genital area.
- Participant has an implanted pacemaker, implantable drug pump or other active medical devices (any medical device that uses electrical energy or other sources of power to make it function).
- Participant is pregnant, nursing or planning a pregnancy (to be confirmed with a negative pregnancy test). Women of childbearing potential must maintain effective contraception during the clinical investigation.
- Participant is enrolled or planning to enrol in another conflicting clinical investigation or was enrolled in an investigational drug trial or medical device investigation within four weeks of enrolment.
- Participant has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation.
- Participant has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has received radiation therapy in the pelvic region.
- Participant has addictive behaviour defined as the abuse of alcohol, cannabis, opioids, or other intoxicating drugs.
- Participant does not speak or understand Danish.
- The following contraception is considered effective: Intrauterine device, hormonal contraceptives such as birth control pills, implants, contraceptive patch, vaginal ring, and contraceptive injection.
Key Trial Info
Start Date :
January 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06091566
Start Date
January 12 2024
End Date
January 1 2026
Last Update
May 6 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8200
2
Herlev Hospital
Herlev, Denmark, 2730
3
Odense University Hospital
Odense, Denmark, 5000